Zura Bio Limited (NASDAQ:ZURA – Get Free Report) has been given an average recommendation of “Buy” by the seven analysts that are currently covering the company, Marketbeat reports.

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and ...

HENDERSON, Nev., February 24, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for ...

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today ...

Get Our Latest Research Report on ZURA Zura Bio Stock Performance Shares of NASDAQ ZURA opened at $1.19 on Tuesday. Zura Bio Limited has a 52-week low of $1.10 and a 52-week high of $6.35. The ...

HENDERSON, Nev., December 23, 2024--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults. HENDERSON, Nev., November 25 ...

HENDERSON, Nev., February 24, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for ...

DALLAS--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, is increasing prices for its vinyl acetate monomer (VAM), vinyl-based emulsions ...